Brain Imaging and Treatment Studies of the Night Eating Syndrome (NCT01401595) | Clinical Trial Compass
CompletedPhase 3
Brain Imaging and Treatment Studies of the Night Eating Syndrome
United States87 participantsStarted 2009-12
Plain-language summary
The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* men and women suffering from NES
* ages 18 to 70 years
* BMI greater than 18.5 kg/m2
Exclusion Criteria:
* Children or adolescents \<18 years
* persons older than 70
* patients with diabetes mellitus
* thyroid disease and other endocrine and metabolic disorders
* use within the past month of any psychotropic medication, oral steroids, diuretics or hypnotics
* current anorexia nervosa or bulimia nervosa
* participation in an organized weight reduction program
* use of antiobesity medication
* an occupation that involves night shifts or other unusual time requirements -Major Depressive Disorder (judged severe)
* Bipolar Disorder
* suicidal risk
* current or past psychosis
* substance use or abuse disorder within the past 6 months